Sammenlign metoder

	Hæmolyseanalyse	CAM-analyse	Elektrospinning	MTT/MTS-assayen
Fagområde	Biomaterialer	Biomaterialer	Biomaterialer	Biomaterialer
Familie	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Oprindelsesår	1950	1974	1934	1983
Ophavsperson	Clinical hematology traditions	Judah Folkman	Anton Formhals	Tatsuro Mosmann
Type	Hemolytic compatibility assay	Developmental biology assay	Fiber fabrication process	Colorimetric assay
Oprindelig kilde	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	Formhals, A. (1934). Process and apparatus for preparing artificial threads. U.S. Patent 1,975,504.	Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), 55-63.
Aliasser	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	electrospun fiber production, electrostatic fiber spinning	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazolium assay, mitochondrial activity assay
Relaterede	4	4	3	4
Resumé	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	Electrospinning is an electrostatic fiber fabrication process that uses a high electric field to draw polymer solutions or melts into nanoscale fibers. Developed by Anton Formhals in the 1930s and refined by researchers including Darrell Reneker in the 1990s, the technique has become foundational to biomaterials engineering, enabling the creation of porous scaffolds for tissue engineering and drug delivery systems.	The MTT assay, introduced by Tatsuro Mosmann in 1983, is a colorimetric method for quantifying cell viability and proliferation by measuring mitochondrial metabolic activity. The method detects the conversion of the water-soluble tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by active mitochondria, producing an insoluble purple formazan precipitate proportional to the number of viable cells. The related MTS assay, which does not require solubilization, offers improved kinetics and is now widely adopted in both academic research and pharmaceutical development.